Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

NCT06948994 is registered in ClinicalTrials.gov with Guangzhou Women and Children's Medical Center as lead sponsor.

NCT NCT06948994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma
Lead sponsor
Guangzhou Women and Children's Medical Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
April 30, 2028
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autologous nk cell, gd2 antibody, neuroblastoma